The GLASSIA BAL Immuno Study is further evaluating the safety and effectiveness of an investigational drug called GLASSIA, also known as alpha1-proteinase inhibitor (human). The effects of this investigational drug will be assessed as augmentation therapy for 25 weeks in adults 18 years of age and older with emphysema caused by alpha-1 deficiency.

Augmentation therapy consists of weekly IV infusions of alpha1-proteinase inhibitor (A1-PI) protein from the blood plasma of healthy human donors to augment (increase) the alpha-1 levels circulating in the blood and lungs of people diagnosed with emphysema.

Who may qualify.

The GLASSIA BAL Immuno Study may be appropriate for those who meet the following criteria:

  • Are adults 18 years of age and older
  • Have a diagnosis of emphysema
  • Have a documented A1-PI genotype that is considered “at risk”
  • Are nonsmokers, or have quit smoking for at least 13 weeks before screening

This clinical research study is currently recruiting in the US and Canada.

Study schedule.

Participants in the GLASSIA BAL Immuno Study will need to:

  • Attend screening visit(s) to determine eligibility; you may need up to two screening visits
  • Participate in the clinical research study for up to 26 weeks, including up to seven visits at a local study site
  • Receive a total of 25 weeks of weekly investigational drug infusions; some infusions will be performed at home
  • Attend all follow-up visits required by the study physician after completing 25 weeks of investigational drug infusions

Additional bronchoalveolar lavage (BAL) testing may be available; no additional visits will be needed for this testing.